维格列汀/二甲双胍(Equmet)与依米明(Twymeeg)联合治疗临床疗效观察

Asploro journal of biomedical and clinical case reports Pub Date : 2023-04-14 DOI:10.36502/2023/asjbccr.6293

H. Bando, H. Yamashita, Y. Kato, K. Ogura, Y. Kato

{"title":"维格列汀/二甲双胍(Equmet)与依米明(Twymeeg)联合治疗临床疗效观察","authors":"H. Bando, H. Yamashita, Y. Kato, K. Ogura, Y. Kato","doi":"10.36502/2023/asjbccr.6293","DOIUrl":null,"url":null,"abstract":"Background: Vildagliptin/Metformin (EquMet) and imeglimin (Twymeeg) are effective oral hypoglycemic agents (OHAs) for patients with type 2 diabetes (T2D).\nCase Presentation: The patient was a 68-year-old male with T2D and fatty liver for several years. In November 2022, his HbA1c had increased to 8.2%, and he was started on Twymeeg, followed by EquMet.\nResults: Over the course of four months, the patient’s HbA1c value successfully decreased from 8.2% to 6.7%, and he did not experience any gastrointestinal adverse effects (GIAEs).\nDiscussion and Conclusion: The combined treatment of EquMet and Twymeeg demonstrated clinical efficacy without any adverse effects. The Trials of IMeglimin for Efficacy and Safety (TIMES) provided various evidence of imeglimin’s effectiveness.","PeriodicalId":93523,"journal":{"name":"Asploro journal of biomedical and clinical case reports","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"Combined Treatment of Vildagliptin/Metformin (Equmet) and Imeglimin (Twymeeg) with Clinical Efficacy\",\"authors\":\"H. Bando, H. Yamashita, Y. Kato, K. Ogura, Y. Kato\",\"doi\":\"10.36502/2023/asjbccr.6293\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Vildagliptin/Metformin (EquMet) and imeglimin (Twymeeg) are effective oral hypoglycemic agents (OHAs) for patients with type 2 diabetes (T2D).\\nCase Presentation: The patient was a 68-year-old male with T2D and fatty liver for several years. In November 2022, his HbA1c had increased to 8.2%, and he was started on Twymeeg, followed by EquMet.\\nResults: Over the course of four months, the patient’s HbA1c value successfully decreased from 8.2% to 6.7%, and he did not experience any gastrointestinal adverse effects (GIAEs).\\nDiscussion and Conclusion: The combined treatment of EquMet and Twymeeg demonstrated clinical efficacy without any adverse effects. The Trials of IMeglimin for Efficacy and Safety (TIMES) provided various evidence of imeglimin’s effectiveness.\",\"PeriodicalId\":93523,\"journal\":{\"name\":\"Asploro journal of biomedical and clinical case reports\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-04-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Asploro journal of biomedical and clinical case reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.36502/2023/asjbccr.6293\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asploro journal of biomedical and clinical case reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36502/2023/asjbccr.6293","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 4

摘要

背景:维格列汀/二甲双胍(EquMet)和伊美米明(Twymeeg)是治疗2型糖尿病(T2D)的有效口服降糖药(OHAs)。病例介绍:患者为男性，68岁，t2dm合并脂肪肝多年。2022年11月，他的糖化血红蛋白上升到8.2%，开始服用Twymeeg，随后服用EquMet。结果:在4个月的治疗过程中，患者的HbA1c值成功地从8.2%降至6.7%，且未出现任何胃肠道不良反应(giae)。讨论与结论:EquMet与Twymeeg联合治疗临床疗效良好，无不良反应。伊美美明的疗效和安全性试验(TIMES)提供了伊美美明有效性的各种证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Combined Treatment of Vildagliptin/Metformin (Equmet) and Imeglimin (Twymeeg) with Clinical Efficacy

Background: Vildagliptin/Metformin (EquMet) and imeglimin (Twymeeg) are effective oral hypoglycemic agents (OHAs) for patients with type 2 diabetes (T2D). Case Presentation: The patient was a 68-year-old male with T2D and fatty liver for several years. In November 2022, his HbA1c had increased to 8.2%, and he was started on Twymeeg, followed by EquMet. Results: Over the course of four months, the patient’s HbA1c value successfully decreased from 8.2% to 6.7%, and he did not experience any gastrointestinal adverse effects (GIAEs). Discussion and Conclusion: The combined treatment of EquMet and Twymeeg demonstrated clinical efficacy without any adverse effects. The Trials of IMeglimin for Efficacy and Safety (TIMES) provided various evidence of imeglimin’s effectiveness.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Asploro journal of biomedical and clinical case reports

自引率

0.00%

发文量